Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function
- 26 September 2023
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (4) , 1403-1414
Abstract
In our study, we examined the efficacy of mTOR (mammalian target of rapamycin) inhibitors, specifically rapamycin (Rap), compared to calcineurin inhibitors (CNIs) in kidney transplantation. By conducting a comprehensive search across reputable databases (EMBASE, Scopus, PubMed, Cochrane, and Crossref), we gathered data for a six-month post-transplantation period. Our analysis revealed that mTOR inhibitor administration resulted in improved glomerular filtration rate (GFR) and serum creatinine levels. However, it is important to note that the mTOR inhibitor group had a higher incidence of acute rejection after biopsy. Through molecular modeling, we observed that Rap exhibited a superior binding affinity for mTOR compared to CNIs’ binding to calcineurin, probably contributing to the transplant rejection. Our meta-analysis supports the cautious use of an optimal mTOR inhibitor in conjunction with careful consideration of clinical features when minimizing CNIs early in the transplantation process. This is because mTOR inhibitors have complementary mechanisms of action, a low nephrotoxicity profile, and favorable outcomes in serum creatinine and GFR, which contribute to improved transplant survival.Keywords
Funding Information
- FSER (2021-0013)
This publication has 46 references indexed in Scilit:
- Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR InhibitorsJournal of Immunology Research, 2013
- Growing experience with mTOR inhibitors in pediatric solid organ transplantationPediatric Transplantation, 2013
- Is it time to give up with calcineurin inhibitors in kidney transplantation?World Journal of Transplantation, 2013
- Calcineurin Inhibitor-Free Immunosuppression in Pediatric Renal TransplantationPediatric Drugs, 2011
- Sirolimus in Kidney Transplantation Indications and Practical Guidelines: De novo Sirolimus-Based Therapy Without Calcineurin InhibitorsTransplantation, 2009
- The Amber biomolecular simulation programsJournal of Computational Chemistry, 2005
- Cellular mechanisms of vascular injury mediated by calcineurin inhibitorsKidney International, 2005
- Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cellsBlood, 2005
- CyclosporineNew England Journal of Medicine, 1989
- DETRIMENTAL EFFECT OF CYCLOSPORINE ON INITIAL FUNCTION OF CADAVER RENAL ALLOGRAFTS FOLLOWING EXTENDED PRESERVATION Results of a randomized Prospective StudyTransplantation, 1986